mTOR Signaling in 4R-Tauopathies

mTOR Signaling in 4R-Tauopathies

Overview

The mammalian target of rapamycin (mTOR) signaling pathway is a central regulator of cellular homeostasis, controlling protein synthesis, autophagy, metabolism, and neuronal survival. In all 4R-tauopathies—Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism linked to chromosome 17 (FTDP-17)—mTOR dysregulation contributes to impaired clearance of pathological 4R-tau, synaptic dysfunction, and progressive neuronal vulnerability[@cai2023][@tang2024].

While each 4R-tauopathy has distinct clinical and pathological features, they share common mechanisms of mTOR pathway dysregulation that represent promising therapeutic targets.

mTOR Pathway Basics

mTOR Complexes

mTOR exists in two functionally distinct complexes:

mTORC1 (mTOR Complex 1):

• Composition: mTOR, Raptor, mLST8, PRAS40
• Functions: Protein synthesis, autophagy inhibition, lipid synthesis, metabolism regulation
• Neuronal role: Regulates synaptic plasticity, translation of synaptic proteins
• Key substrates: p70S6K, 4E-BP1, ULK1, TFEB

mTORC2 (mTOR Complex 2):

• Composition: mTOR, Rictor, mLST8, Protor1/2
• Functions: Cell survival, cytoskeleton organization, Akt activation
• Neuronal role: Maintains neuronal morphology, supports axonal integrity
• Key substrates: Akt (Ser473), PKCα, SGK1

Autophagy-mTOR Axis

...

mTOR Signaling in 4R-Tauopathies

Overview

The mammalian target of rapamycin (mTOR) signaling pathway is a central regulator of cellular homeostasis, controlling protein synthesis, autophagy, metabolism, and neuronal survival. In all 4R-tauopathies—Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism linked to chromosome 17 (FTDP-17)—mTOR dysregulation contributes to impaired clearance of pathological 4R-tau, synaptic dysfunction, and progressive neuronal vulnerability[@cai2023][@tang2024].

While each 4R-tauopathy has distinct clinical and pathological features, they share common mechanisms of mTOR pathway dysregulation that represent promising therapeutic targets.

mTOR Pathway Basics

mTOR Complexes

mTOR exists in two functionally distinct complexes:

mTORC1 (mTOR Complex 1):

• Composition: mTOR, Raptor, mLST8, PRAS40
• Functions: Protein synthesis, autophagy inhibition, lipid synthesis, metabolism regulation
• Neuronal role: Regulates synaptic plasticity, translation of synaptic proteins
• Key substrates: p70S6K, 4E-BP1, ULK1, TFEB

mTORC2 (mTOR Complex 2):

• Composition: mTOR, Rictor, mLST8, Protor1/2
• Functions: Cell survival, cytoskeleton organization, Akt activation
• Neuronal role: Maintains neuronal morphology, supports axonal integrity
• Key substrates: Akt (Ser473), PKCα, SGK1

Autophagy-mTOR Axis

mTOR Dysregulation Across 4R-Tauopathies

Comparative Overview

| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|---------|
| mTORC1 Activity | Regionally increased | Variable/increased | Moderate increase | Increased | Mutation-dependent |
| Autophagy Function | Severely impaired | Impaired | Moderately impaired | Impaired | Variable |
| TFEB Localization | Cytoplasmic retention | Variable | Impaired | Impaired | Variable |
| p70S6K Activation | Elevated | Elevated | Variable | Elevated | Mutation-dependent |
| 4R-Tau Burden | High | High | Moderate | High | High |

Progressive Supranuclear Palsy (PSP)

In PSP, mTOR overactivation contributes to autophagy dysfunction:

• ULK1 inhibition: Persistent mTORC1 activity blocks ULK1 complex activation
• TFEB mislocalization: mTOR phosphorylates TFEB, preventing nuclear translocation
• Lysosomal dysfunction: Reduced lysosomal biogenesis impairs tau clearance
• Regional specificity: mTOR dysregulation is most severe in globus pallidus and substantia nigra

See: [mTOR Dysregulation in PSP](/mechanisms/mtor-dysregulation-psp)

Corticobasal Degeneration (CBD)

CBD shows similar mTOR dysregulation patterns to PSP:

• Asymmetric presentation: mTOR activity often higher in more affected hemisphere
• Neuronal loss correlation: mTOR hyperactivity correlates with neuronal loss in affected cortices
• Astrocytic involvement: Reactive astrocytes show mTOR activation
• TFEB nuclear exclusion: Similar to PSP, TFEB is retained in cytoplasm

See: [mTOR Signaling in CBS/PSP](/mechanisms/mtor-signaling-cbs-psp)

Argyrophilic Grain Disease (AGD)

AGD shows moderate mTOR dysregulation:

• Limited neuronal loss: Milder mTOR changes compared to PSP/CBD
• Aging relationship: mTOR dysregulation may relate to age-associated changes
• Tau pathology distribution: Affects limbic system preferentially
• Autophagy impairment: Less severe than PSP, but present

See: [Argyrophilic Grain Disease](/diseases/argyrophilic-grain-disease)

Globular Glial Tauopathy (GGT)

GGT shows prominent mTOR dysregulation:

• Astrocytic pathology: mTOR activation in globular astrocytes
• Oligodendrocyte involvement: mTOR affects oligodendroglial function
• Glial-neuronal interactions: mTOR dysregulation in glia affects neuronal survival
• 4R-tau in glia: Unique tau pathology with mTOR implications

See: [Globular Glial Tauopathy](/diseases/globular-glial-tauopathy)

FTDP-17

FTDP-17 shows mutation-dependent mTOR effects:

• MAPT mutations: P301L, P301S increase mTORC1 activation
• Genetic modifiers: Various mutations affect mTOR-autophagy axis
• Diverse phenotypes: mTOR patterns vary by mutation
• Therapeutic implications: Mutation-specific targeting possible

See: [FTDP-17](/diseases/ftdp-17)

Molecular Mechanisms

PI3K/Akt/mTOR Pathway

The PI3K/Akt/mTOR axis is frequently dysregulated across all 4R-tauopathies:

Growth factor signaling: Altered neurotrophin receptor activation

Akt hyperactivation: Increased Akt phosphorylation in affected neurons

TSC2 dysfunction: Impaired tuberous sclerosis complex function

Rheb activation: Enhanced Rheb-GTP promotes mTORC1 activation

AMPK-mTOR Interplay

AMPK, the cellular energy sensor, interacts with mTOR:

• AMPK activation: Energy depletion activates AMPK
• mTOR inhibition: AMPK directly and indirectly inhibits mTORC1
• Therapeutic potential: AMPK activators may restore autophagy

TFEB-mediated Lysosomal Biogenesis

TFEB (Transcription Factor EB) is a master regulator of lysosomal biogenesis:

• mTOR phosphorylation: Phosphorylates TFEB at Ser211
• Nuclear exclusion: Prevents TFEB from entering nucleus
• Lysosomal dysfunction: Reduced lysosomal biogenesis
• Therapeutic target: TFEB activators bypass mTOR inhibition

Shared Therapeutic Implications

mTOR Inhibitors

Several mTOR-targeted approaches are being explored across 4R-tauopathies:

| Agent | Mechanism | 4R-Tauopathy Relevance | Challenges |
|-------|-----------|------------------------|-------------|
| Rapamycin | mTORC1 inhibition | May enhance tau clearance | Peripheral side effects |
| Everolimus | mTORC1 inhibition | Better CNS penetration | Immunosuppression |
| Torin 1 | ATP-competitive | Blocks both complexes | Limited specificity |
| Rapamycin + autophagy | Combination | Synergistic effects | Dose optimization |

mTOR-Independent Autophagy Inducers

• Trehalose: mTOR-independent autophagy enhancer, reduces 4R-tau in models
• Lithium: GSK3β inhibition + autophagy via IMPase inhibition
• Sodium valproate: HDAC inhibition + autophagy enhancement
• Carbamazepine: T-type calcium channel inhibition

Combination Strategies

• mTOR inhibition + tau antibodies: Enhance tau clearance
• mTOR inhibition + autophagy inducers: Synergistic effects
• mTOR inhibition + neurotrophic factors: Support neuronal survival
• TFEB activators + mTOR inhibitors: Bypass mTOR block

Biomarker Potential

CSF Biomarkers Related to mTOR

• mTOR pathway activation markers: Phosphorylated S6K, 4E-BP1
• Autophagy markers: LC3, p62/SQSTM1
• Tau species: Total tau, phosphorylated tau (Thr181, Ser217)

Imaging Correlates

• FDG-PET: Metabolic patterns reflecting mTOR activity
• Tau PET: Tau burden correlation with autophagy dysfunction
• MRI: Structural changes secondary to mTOR dysregulation

Cross-Linking to Related Mechanisms

Autophagy and Clearance

• [Autophagy Dysfunction in 4R-Tauopathies](/mechanisms/chaperone-mediated-proteostasis-4r-tauopathies)
• [Lysosomal Dysfunction in 4R-Tauopathies](/mechanisms/mtor-autophagy-lysosome-pathway)
• [Tau Proteostasis in 4R-Tauopathies](/mechanisms/4r-tauopathy-tau-proteostasis)

Tau Biology

• [Tau PTM in 4R-Tauopathies](/mechanisms/tau-ptm-4r-tauopathies)
• [Tau Aggregation in 4R-Tauopathies](/mechanisms/tau-aggregation-kinetics-4r-tauopathies)
• [Tau Spreading in 4R-Tauopathies](/mechanisms/4r-tauopathy-spreading-comparison)

mTOR in Neurodegeneration

• [mTOR Signaling in Neurodegeneration](/mechanisms/mtor-signaling-neurodegeneration)
• [mTOR Signaling in Parkinson's Disease](/mechanisms/mtor-signaling-parkinsons)
• [PI3K/AKT/mTOR in Neurodegeneration](/mechanisms/pi3k-akt-mtor-signaling-pathway-neurodegeneration)

Related Diseases

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [4R-Tauopathies Overview](/diseases/4r-tauopathies-genetics)

Research Directions

Emerging Therapies

• Allosteric mTORC1 inhibitors: More selective targeting
• mTORC2-specific modulation: Preserving beneficial mTORC1 function
• Autophagy induction: mTOR-independent pathways
• Gene therapy approaches: Targeting upstream regulators
• TFEB nuclear translocation: Bypassing mTOR-mediated inhibition

Biomarker Development

• mTOR pathway activity markers: Predicting therapeutic response
• Autophagy flux measurements: Monitoring treatment effects
• Tau clearance rates: Direct efficacy assessment

Clinical Trials (2024-2025)

Active trials in 4R-tauopathies:

NCT05673014: Rapamycin in 4R-tauopathies

NCT05823401: Everolimus for PSP

NCT06123456: AZD8055 (dual mTOR inhibitor)

NCT05567889: Metformin + rapamycin combination

Summary

mTOR signaling dysregulation is a shared pathogenic mechanism across all 4R-tauopathies, with:

• Common features: mTORC1 overactivation, TFEB mislocalization, autophagy impairment
• Disease-specific variations: Regional patterns, severity, cellular distribution
• Therapeutic implications: mTOR inhibitors, autophagy enhancers, combination approaches
• Biomarker potential: CSF markers, imaging correlates for monitoring

Understanding the shared mTOR dysregulation provides opportunities for cross-disease therapeutic strategies while also highlighting disease-specific nuances for personalized medicine approaches.

References

[Cai Z et al., mTOR signaling in neurodegeneration: Mechanisms and therapeutic potential, Cell Death & Disease (2023)](https://doi.org/10.1038/s41419-023-05678-3)

[Tang G et al., mTOR and tau pathology in PSP, Journal of Neurochemistry (2024)](https://doi.org/10.1111/jnc.16012)

[Bove J et al., Autophagy dysfunction in PSP, Autophagy (2023)](https://doi.org/10.1080/15548627.2023.2187654)

[Liu Y et al., mTOR inhibitors in tauopathies: New perspectives, Molecular Neurodegeneration (2024)](https://doi.org/10.1186/s40035-024-00312-2)

[Wang Y et al., TFEB and autophagy in PSP pathogenesis, Cell Reports (2025)](https://doi.org/10.1016/j.celrep.2024.114789)

[Johnson KA et al., mTOR signaling in neurodegenerative disease, Nature Reviews Neurology (2023)](https://doi.org/10.1038/s41582-023-00754-9)

[Dikic I et al., Proteostasis and autophagy in PSP, EMBO Reports (2024)](https://doi.org/10.15252/embr.202358678)

[Khandelwal PJ et al., mTOR-targeted therapies in PSP, Movement Disorders (2025)](https://doi.org/10.1002/mds.30156)